Key Highlights
- Net Revenue was USD 559 thousand against an estimate of USD 244.28 thousand.
- Net loss per share was USD 0.10 against an estimate of a USD 0.24 loss.
- Net loss was USD 3.58 million, compared with USD 10.85 million.
- Cash and cash equivalents were USD 11.02 million at September 30, 2026.
Insight Molecular Diagnostics (NASDAQ:IMDX) reported net revenue of USD 559 thousand for the third quarter of 2026, compared with USD 260 thousand in the prior-year quarter, against an estimate of USD 244.28 thousand. Basic and diluted net loss per share was USD 0.10, compared with USD 0.34, against an estimate of a USD 0.24 loss.
Net loss was USD 3.58 million, compared with USD 10.85 million. The company, formerly known as Oncocyte Corporation, describes its mission as expanding access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category.
Third Quarter Results
Cost of revenues was USD 139 thousand, compared with USD 121 thousand, and Gross Profit was USD 420 thousand, compared with USD 139 thousand. Research and Development expenses were USD 3.79 million, compared with USD 3.88 million, sales and Marketing expenses were USD 1.61 million, compared with USD 1.39 million, and general and administrative expenses were USD 2.79 million, compared with USD 2.55 million.
The company recorded a change in Fair Value of contingent consideration of negative USD 4.09 million, compared with USD 3.38 million. Total operating expenses were USD 4.10 million, compared with USD 11.19 million, and the loss from operations was USD 3.68 million, compared with USD 11.05 million. Total other income, net, was USD 97 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, net revenue was USD 830 thousand, compared with USD 2.92 million, and gross profit was USD 592 thousand, compared with USD 1.80 million. Research and development expenses were USD 13.23 million, compared with USD 10.07 million, and sales and marketing expenses were USD 5.93 million, compared with USD 4.05 million.
The loss from operations for the nine months was USD 19.49 million, compared with USD 27.69 million, and the net loss was USD 19.13 million, compared with USD 27.27 million. Net loss per share was USD 0.53, compared with USD 0.91. Weighted average shares outstanding for the quarter were 36,863 thousand, compared with 32,033 thousand.
Balance Sheet and Going Concern Disclosure
Cash and cash equivalents were USD 11.02 million at September 30, 2026, compared with USD 11.58 million at December 31, 2025. Total current liabilities were USD 9.51 million, compared with USD 12.08 million. Total Assets were USD 21.74 million, compared with USD 25.76 million, and total liabilities were USD 45.92 million, compared with USD 57.22 million.
The filing includes a going concern evaluation that discusses substantial doubt about the company's ability to continue as a going concern within one year after the date the financial statements were issued.
Insight Molecular Diagnostics Q3 2026 Earnings: Key Takeaways
Insight Molecular Diagnostics reported third quarter 2026 net revenue of USD 559 thousand and a net loss of USD 3.58 million. Cash and cash equivalents were USD 11.02 million at September 30, 2026.






Please wait processing your request...